Edwige Baudry, Natacha Naoun, Edouard Auclin, Carolina Saldana, Philippe Barthelemy, Lionnel Geoffrois, Constance Thibault, Manon de Vries-Brilland, Delphine Borchiellini, Denis Maillet, Laure Hirsch, Charles Vauchier, Lucia Carril-Ajuria, Emeline Colomba, Alice Bernard-Tessier, Bernard Escudier, Ronan Flippot, Laurence Albigès
BACKGROUND: Despite metastatic renal cell carcinoma (mRCC) expanded treatment options, disease progression ultimately occurs for most patients. Rechallenge may be a compelling strategy in a refractory setting. Cabozantinib is the standard of care in first and later lines of therapy, but its activity in rechallenge is unknown. METHODS: This retrospective study assessed the efficacy and safety of cabozantinib rechallenge, as defined by a second exposure after an interval of ≥3 months without treatment or ≥1 other treatment line, in patients with mRCC...
August 18, 2023: European Journal of Cancer